Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Entain Full-year Loss Widens, But Revenue Rises; Ups Dividend; Backs FY26 EBITDA Outlook (AFX) +++ ENTAIN Aktie +4,64%

KALA BIO Aktie

 >KALA BIO Aktienkurs 
0.339 EUR    +13.0%    (TradegateBSX)
Ask: 0.339 EUR / 6440 Stück
Bid: 0.294 EUR / 7011 Stück
Tagesumsatz: 7463 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
KALA BIO Aktie über LYNX handeln
>KALA BIO Performance
1 Woche: -9,3%
1 Monat: -15,4%
3 Monate: -63,3%
6 Monate: -97,5%
1 Jahr: -95,1%
laufendes Jahr: -38,5%
>KALA BIO Aktie
Name:  KALA BIO INC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US4831192020 / A3DWPS
Symbol/ Ticker:  27F0 (Frankfurt) / KALA (NASDAQ)
Kürzel:  FRA:27F0, ETR:27F0, 27F0:GR, NASDAQ:KALA
Index:  -
Webseite:  https://www.kalarx.com/
Profil:  Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. Its primary function is to address unmet needs in t..
>Volltext..
Marktkapitalisierung:  304.97 Mio. EUR
Unternehmenswert:  312.57 Mio. EUR
Umsatz:  -
EBITDA:  -35.63 Mio. EUR
Nettogewinn:  -30.91 Mio. EUR
Gewinn je Aktie:  -5.12 EUR
Schulden:  25.83 Mio. EUR
Liquide Mittel:  18.19 Mio. EUR
Operativer Cashflow:  -27.63 Mio. EUR
Bargeldquote:  0.65
Umsatzwachstum:  -
Gewinnwachstum:  12.72%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  KALA BIO
Letzte Datenerhebung:  05.03.26
>KALA BIO Kennzahlen
Aktien/ Unternehmen:
Aktien: 911.33 Mio. St.
Frei handelbar: 93.9%
Rückkaufquote: 0.19%
Mitarbeiter: 38
Umsatz/Mitarb.: -
Analysten:
Analystenrating: No rating
Kursziel: -
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -90.62%
Eigenkaprendite: -
>KALA BIO Peer Group
Gesundheit, Augenmedizin
 
04.03.26 - 19:33
KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model (Benzinga)
 
KALA BIO (KALA) shares rose after unveiling a strategic initiative to build an on-premises AI infrastructure platform for biotech. Importance Rank:  1 read more...
04.03.26 - 13:45
Kala Bio rises on plans to leverage AI (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.03.26 - 12:33
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Resea (GlobeNewswire EN)
 
ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”), a clinical-stage biopharmaceutical company, today announced a strategic initiative to build a biotechnology industry dedicated, on-premises artificial intelligence (“AI”) infrastructure platform, designed to be deployed directly within biotech and pharmaceutical client environments, enabling companies across the life sciences sector to unlock additional potential of their proprietary biological data without ever surrendering control of it....
05.01.26 - 22:12
KALA BIO Settles Approximately $10.6 million of Debt (GlobeNewswire EN)
 
ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations....
05.12.25 - 20:39
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire EN)
 
ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof)....
04.12.25 - 17:01
KALA BIO to raise $10 mln in registered direct offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.12.25 - 16:48
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire EN)
 
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 5, 2025, subject to the satisfaction of customary closing conditions....
04.12.25 - 07:39
Why Did KALA BIO Shares Jump Over 22% After Hours? (Benzinga)
 
KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued year-to-date losses. read more...
01.12.25 - 15:18
Kala Bio-Aktie schießt nach 6-Millionen-Dollar-Investment und CEO-Wechsel in die Höhe/n (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
01.12.25 - 13:03
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar (GlobeNewswire EN)
 
Investment to support the continued evaluation and redevelopment of KALA's product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction Investment to support the continued evaluation and redevelopment of KALA's product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction...
26.11.25 - 07:39
What Sparked KALA BIO′s Nearly 38% Surge Overnight? (Benzinga)
 
KALA BIO shares surged over 37% in after-hours trading following a private placement, loan settlement, and leadership changes. read more...
25.10.25 - 03:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Kala Pharmaceuticals im Wert von 39647 USD (Insiderkauf)
 
Bazemore, Todd - Aufsichtsrat - Tag der Transaktion: 2025-10-22...
25.10.25 - 03:01
Insiderhandel: Vorstand verkauft Aktien von Kala Pharmaceuticals im Wert von 38801 USD (Insiderkauf)
 
Brazzell, Romulus K. - Vorstand - Tag der Transaktion: 2025-10-22...
25.10.25 - 03:01
Insiderhandel: CHIEF BUSINESS OFFICER verkauft Aktien von Kala Pharmaceuticals im Wert von 17269 USD (Insiderkauf)
 
Kharabi, Darius - Vorstand - Tag der Transaktion: 2025-10-22...
25.10.25 - 03:01
Insiderhandel: CHIEF FINANCIAL OFFICER verkauft Aktien von Kala Pharmaceuticals im Wert von 26751 USD (Insiderkauf)
 
Reumuth, Mary - Vorstand - Tag der Transaktion: 2025-10-22...
25.10.25 - 03:01
Insiderhandel: CHIEF FINANCIAL OFFICER verkauft Aktien von Kala Pharmaceuticals im Wert von 793 USD (Insiderkauf)
 
Reumuth, Mary - Vorstand - Tag der Transaktion: 2025-10-23...
25.10.25 - 03:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Kala Pharmaceuticals im Wert von 125464 USD (Insiderkauf)
 
Iwicki, Mark T. - Aufsichtsrat - Tag der Transaktion: 2025-10-23...
08.10.25 - 19:00
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure (Zacks)
 
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options....
03.10.25 - 02:01
Insiderhandel: Insider verkauft Aktien von Kala Pharmaceuticals im Wert von 710730 USD (Insiderkauf)
 
Baker Bros. Advisors Lp - Sonstiges / enge Beziehung - Tag der Transaktion: 2025-10-01...
03.10.25 - 02:01
Insiderhandel: Insider verkauft Aktien von Kala Pharmaceuticals im Wert von 345993 USD (Insiderkauf)
 
Baker Bros. Advisors Lp - Sonstiges / enge Beziehung - Tag der Transaktion: 2025-09-30...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!